DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION			
250 Marquette Ave, Ste. 600	7/12/2021-8/2/2021*			
Minneapolis, MN 55401 (612)334-4134	FEI NUMBER 3014483112			
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED	<u>'</u>			
Craig E. Else, Director / COO				
FIRM NAME	STREET ADDRESS			
IntegraDose Compounding Services LLC	719 Kasota Ave Se			
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED			
Minneapolis, MN 55414-2842	Outsourcing Facility			

This document lists observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any questions, please contact FDA at the phone number and address above.

DURING AN INSPECTION OF YOUR FIRM WE OBSERVED:

OBSERVATION 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established, written and followed.

Specifically,

- -Individual media fills performed by personnel are limited to vial units and not representative of production quantities and process. For example, Lot (b) (4), produced on 7/12/2021, filled and capped approximately syringes of drug product using a repeater pump.
- -On 6/28/21, the **(b) (4)** (b) (4) cleaning was not performed due to an HVAC Discrepancy and later that day production was performed for Cefazolin Lot #'s **(b) (4)**. These lots were approved for Final Release by Quality on 7/20/21. This HVAC event was not recorded in the Cleanroom Event Log, therefore not reviewed by the quality unit.

OBSERVATION 2

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

-On 7/19/21, we observed a video from 7/1/21 from room (b) (4), an ISO 7 Cleanroom, where a square

SEE REVERSE OF THIS PAGE Anthony J Ladner, Investigator Ross J Grigsby, Investigator Kevin P Regan, Investigator	Anthony J Ladner Anthony J Ladner Signed Sp / Anthony J Ladner -63 Date Signed: 09-62-2021 X 08-50; 8	8/2/2021
--	--	----------

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 1 of 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION			
DISTRICT ADDRESS AND PHONE NUMBER	DATE(S) OF INSPECTION		
250 Marquette Ave, Ste. 600	7/12/2021-8/2/2021*		
Minneapolis, MN 55401	FEI NUMBER		
(612)334-4100 Fax: (612)334-4134	3014483112		
NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED			
Craig E. Else, Director / COO			
FIRM NAME	STREET ADDRESS		
IntegraDose Compounding Services LLC	719 Kasota Ave Se		
CITY, STATE, ZIP CODE, COUNTRY	TYPE ESTABLISHMENT INSPECTED		
Minneapolis, MN 55414-2842	Outsourcing Facility		

on the floor was missed in mopping. Furthermore, in room (b) (4), an ISO 7 Cleanroom, a mop head was used for two squares instead of being changed after each square, as stated in the Cleaning SOP EV-5010 Cleaning Program: 503B Cleanroom Rev. 02 Effective 8/17/20. During these same cleanings, a worker touched the bottom of the dirty mop head with their gloved hand while changing the mop head and did not change gloves nor sanitize gloves, and subsequently touched cart handles, chairs and door handles. The cleaners also used a back-and-forth mopping pattern while mopping the floor as opposed to a figure-8 pattern.

-On 7/19/21 we observed a worker on 7/1/21 spray (b) (4) detergent and (b) (4) for disinfecting on a stainless-steel cart and not wait the designated dwell time to remove the product as stated in the Cleaning SOP EV-5010 Cleaning Program: 503B Cleanroom Rev. 02 Effective 8/17/20.

-On 7/19/21 we observed a compounding technician on 7/2/21 spray(b) (4) and for disinfecting on a stainless-steel cart and not wait the designated dwell time to remove the product as stated in the Cleaning SOP EV-5010 Cleaning Program: 503B Cleanroom Rev. 02 Effective 8/17/20.

During our walk-thru on 7/15/21 we observed the following:

- Apparent rust/corrosion on utility carts used in the ISO 8 area to import supply kits containing IV bags and syringes and shelving used in the ISO 8 area to hold cleaning supplies and sterile wipes as well as a Hepa filter grate and return air grate in room (b) (4).
- -What appears to be significant dust build up on the door brush for the (b)(4) overhead door within the ISO-8 area Room (b)(4) where final visual inspection is performed.

SEE REVERSE OF THIS PAGE Anthony J Ladner, Investigator Ross J Grigsby, Investigator Kevin P Regan, Investigator	Anthony J.Ladner Investiga or Signed By Anthony J.Ladner-63 Os dis. 8	8/2/2021
--	---	----------

FORM FDA 483 (09/08) PREVIOUS EDITION OBSOLETE INSPECTIONAL OBSERVATIONS PAGE 2 of 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION				
250 Marguette	e Ave, Ste. 600		DATE(S) OF INSPECTION 7/12/2021-8/2/2021*	
Minneapolis,	*/		FEI NUMBER	
	Fax: (612)334-4134		3014483112	
NAME AND TITLE OF INDIVIDUA	L TO WHOM REPORT ISSUED			
-	e, Director / COO			
Integralose (Compounding Services LLC	street Address 719 Kasota Ave Se		
CITY, STATE, ZIP CODE, COUNT		TYPE ESTABLISHME		
Minneapolis,	MN 55414-2842	Outsourc	ccing Facility	
-Black residue on the floor next to the wheel of Hood (b) (4) in the ISO 7 area room (b) (4), and or the floor near the wheels of a storage cart in the ISO 8 room (b) (4). -White flecks on the floor in several areas of the ISO 8 rooms which appear to be from demarcation line deterioration that could be tracked into other areas.				
OBSERVATION The responsibility followed.		e quality co	control unit are not in writing and fully	
Specifically,				
deadline as def Eff. 12/2018 ar For example: 1) EV-0396 "C Occurrence: 03	fined in SOP PQ-5075.1 "Corrective of PQ-5245 "Event Investigations" efazolin hood ((b) (4)) pressure /30/2020 ersonnel EM (forehead) > action line in the state of the state	ve and Prev Eff. 12/201 0, power fa	failure during (b) (4) "Date of	
3) CA-0051 "In Date Issued: 09	inplement cleaning step (b) (4) 0/23/2020		for applicable batches."	
4) CA-0055 "P Issued: 12/09/2		E E E	g of manufactured batches (b) (4) nge has been proven effective." Date	
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Anthony J Ladner, Investigate Ross J Grigsby, Investigator Kevin P Regan, Investigator	r	Antibory J Ladner Investiga or Signed Str. Antibory J Ladner - 63 Date States CR-202-2021	

INSPECTIONAL OBSERVATIONS

FORM FDA 483 (09/08)

PREVIOUS EDITION OBSOLETE

PAGE 3 of 5 PAGES

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION					
DISTRICT ADDRESS AND PHON	IE NUMBER		DATE(S) OF INS		
V	te Ave, Ste. 600		// 12/20 FEI NUMBER	021-8/2/2021*	
	apolis, MN 55401 334-4100 Fax:(612)334-4134		3014483	3112	
NAME AND TITLE OF INDIVIDUA	AL TO WHOM REPORT ISSUED		90		
Craig E. Else	e, Director / COO				
FIRM NAME		STREET ADDRESS	111 01		
IntegraDose (Compounding Services LLC	719 Kaso		Se	
	MN 55414-2842	Outsourcing Facility			
Quality fails to transfer all hand-written events from batch records to their internal event log. For example, batch record (b) (4) contains a hand-written note "Particle counter unable to obtain (b) (4) reading after runs. Re-cleaned was not transferred to their internal event log. Quality failed to validate cleaning dwell times listed in SOP EV5010.2 Cleaning Program – 503B Cleanroom Effective 12/2019 for the detergent (b) (4) and disinfectant (b) (4) used in cleaning the ISO 5 hood. Additionally, the firm failed to provide justification for diluting their detergent (b) (4) with (b) (4) as shown in Batch record (b) (4) Lot# (b) (4) .					
OBSERVATIO			67 0 0	10 - 12 - 11	
3 to 2 to	ing areas are deficient regarding sys	stems for m	aintaining	g any equipment u	sed to control
the aseptic cond	ittons.				
Specifically,					
-Dynamic smoke studies performed in the ISO-5 hoods were not representative of conditions observed during production. The smoke study performed only included (b) (4) On 7/12/21 during production of Lot (b) (4) up to 10 boxes of syringes, multiple packages of caps, two IV bags, and a balance were observed inside the ISO-5 processing area. - After installation of a new (b) (4) Hood (b) (4) located in ISO 7 room (b) (4) on 4/10/21 a smoke study was not performed. This hood is currently in use for Cefazolin production and was used in producing multiple lots including Lot (b) (4)					
SEE REVERSE OF THIS PAGE	EMPLOYEE(S) SIGNATURE Anthony J Ladner, Investigate Ross J Grigsby, Investigator Kevin P Regan, Investigator			Anthony J Ladiner Investiga or Signed By Anthony J Ladiner-63 Signed By Anthony J Ladiner-63 Disciss 8	B/2/2021

DEPARTMENT OF HEALTH AND HUMAN SERVICES FOOD AND DRUG ADMINISTRATION DISTRICT ADDRESS AND PHONE NUMBER 250 Marquette Ave, Ste. 600 7/12/2021-8/2/2021* Minneapolis, MN 55401 3014483112 (612)334-4100 Fax: (612)334-4134 NAME AND TITLE OF INDIVIDUAL TO WHOM REPORT ISSUED Craig E. Else, Director / COO FIRM NAME STREET ADDRESS IntegraDose Compounding Services LLC 719 Kasota Ave Se CITY, STATE, ZIP CODE, COUNTRY TYPE ESTABLISHMENT INSPECTED

-On 7/20/2021 we observed video of the cleaning performed of an ISO-7 room (b) (4) on 7/2/2021 where the cleaning crew moved the ISO 5 LAF Hoods to clean behind them. Your firm verbally stated that the hoods are moved (b) (4) for routine cleaning. Your firm fails to re-qualify hoods each time they are moved for cleaning.

Outsourcing Facility

*DATES OF INSPECTION

Minneapolis, MN 55414-2842

7/12/2021(Mon), 7/13/2021(Tue), 7/14/2021(Wed), 7/15/2021(Thu), 7/19/2021(Mon), 7/20/2021(Tue), 7/22/2021(Thu), 7/27/2021(Tue), 8/02/2021(Mon)





SEE REVERSE OF THIS PAGE EMPLOYEE(S) SIGNATURE

Anthony J Ladner, Investigator Ross J Grigsby, Investigator Kevin P Regan, Investigator



DATE ISSUED 8/2/2021

PAGE 5 of 5 PAGES

The observations of objectionable conditions and practices listed on the front of this form are reported:

- 1. Pursuant to Section 704(b) of the Federal Food, Drug and Cosmetic Act, or
- 2. To assist firms inspected in complying with the Acts and regulations enforced by the Food and Drug Administration.

Section 704(b) of the Federal Food, Drug, and Cosmetic Act (21 USC 374(b)) provides:

"Upon completion of any such inspection of a factory, warehouse, consulting laboratory, or other establishment, and prior to leaving the premises, the officer or employee making the inspection shall give to the owner, operator, or agent in charge a report in writing setting forth any conditions or practices observed by him which, in his judgment, indicate that any food, drug, device, or cosmetic in such establishment (1) consists in whole or in part of any filthy, putrid, or decomposed substance, or (2) has been prepared, packed, or held under insanitary conditions whereby it may have become contaminated with filth, or whereby it may have been rendered injurious to health. A copy of such report shall be sent promptly to the Secretary."